deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01503242

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Sponsor: Fred Hutchinson Cancer Center

Conditions Plasma Cell Myeloma Refractory Plasma Cell Myeloma
Interventions Allogeneic Hematopoietic Stem Cell Transplantation Cyclosporine Fludarabine Phosphate Mycophenolate Mofetil Peripheral Blood Stem Cell Transplantation Total-Body Irradiation Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Updated 12 times since 2017 Last updated: Dec 6, 2019 Started: Jan 9, 2012 Primary completion: Jun 6, 2017 Completion: Dec 6, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01503242, this PHASE1 trial focuses on Plasma Cell Myeloma and Refractory Plasma Cell Myeloma and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~May 2017 · 3 months · monthly snapshotRecruiting~May 2017 – ~Oct 2017 · 5 months · monthly snapshotSuspended~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotActive Not Recruiting~Dec 2018 – ~Dec 2019 · 12 months · monthly snapshotActive Not Recruiting~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshotActive Not Recruiting~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshotCompleted~Jan 2021 – ~May 2022 · 16 months · monthly snapshotCompleted~May 2022 – ~Jul 2024 · 26 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — May 2022 [monthly]

    Completed PHASE1

  5. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 7 earlier versions

  1. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2018 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Suspended → Active Not Recruiting

  5. May 2017 — Oct 2017 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  6. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  7. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations